Sanofi Genzyme Announces Multiple Sclerosis Research Collaboration with the Johns Hopkins School of Medicine
May 16 2016 - 9:00AM
Business Wire
Sanofi Genzyme, the specialty care global business unit of
Sanofi, announced today a research collaboration with the Johns
Hopkins School of Medicine that will focus on novel strategies
aimed at advancing the understanding of underlying causes of
disease progression in multiple sclerosis (MS). The collaboration,
under guidance by a joint committee of representatives from Sanofi
Genzyme and the Johns Hopkins Multiple Sclerosis Center, will
leverage certain technologies and methodologies designed to inform
new therapeutic approaches to treating disease progression.
As one of the largest clinical and research MS centers globally,
the Johns Hopkins Multiple Sclerosis Center brings a breadth of
expertise and an established foundation of novel research
approaches that complement Sanofi Genzyme’s MS research
priorities.
“While there are currently no approved treatments for
progressive forms of MS, the research landscape is evolving to
where we are learning more about the underlying biology of disease
progression,” said Michael Panzara, MD, Head of MS, Neurology and
Ophthalmology Therapeutic Area, Global Development, Sanofi Genzyme.
“Collaborations like this are important to advancing interventional
strategies that slow relentless progression in MS. We are excited
about the potential of this collaboration to advance our
understanding of disease progression, enabling more rapid
development of the next generation of MS therapies.”
Sanofi Genzyme’s MS research pipeline includes collaborations
with academic medical centers that explore the pathogenesis of MS
and potential novel therapeutics. Initiatives include identifying
biomarkers of disease progression and exploring strategies to
address neurodegeneration, considered to be a key factor driving
disability accumulation in MS.
About SanofiSanofi, a global healthcare leader,
discovers, develops and distributes therapeutic solutions focused
on patients' needs. Sanofi is organized into five global business
units: Diabetes and Cardiovascular, General Medicines and Emerging
Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is
listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Genzyme focuses on developing specialty treatments for
debilitating diseases that are often difficult to diagnose and
treat, providing hope to patients and their families. Learn more
at www.sanofigenzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation.
Sanofi® is a registered trademark of Sanofi. All rights
reserved.
Sanofi Forward-Looking StatementsThis press release
contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
the Group’s ability to benefit from external growth opportunities,
trends in exchange rates and prevailing interest rates, the impact
of cost containment initiatives and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2015. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160516005953/en/
Sanofi GenzymeMedia RelationsErin Walsh,
+1-617-768-6881Erin.Walsh@genzyme.com
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2024 to May 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From May 2023 to May 2024